Biological activity of conjugates of muramyl dipeptides with batracylin derivatives.
Antitumour activity of batracylin (BAT), muramyldipeptide (MDP) and four immunomodulatory conjugates of BAT with MDP were evaluated in the study. The activity was assessed using viability tests performed in the cultures of tumour cell lines of different tissue origin such as WEHI 164 (fibrosarcoma), K562 (leukaemia), and Ab (melanoma), populations of immune cells isolated from peripheral blood, and the tumour cells mixed with immune cells. An intensity of cell death caused by the analogues was measured using flow cytometry analysis as subG1 peak and the distinction between necrotic and apoptotic DNA cleavage during cell death was performed using DNA fragmentation assay. The compounds 11c, 11e and 11h managed to kill WEHI 164 cells in the presence of immune cells in apoptotic manner while BAT and conjugate 11a caused necrosis at the same time. Necrotic pattern of DNA cleavage was also noted in all cultures containing K562 and Ab cells. BAT and MDP caused necrosis in the cultures of pure immune cells, while the conjugates did not affect these cultures at all. Surprisingly, some analogues increased viability of K562 and Ab cells. Low toxicity and ability to induce apoptosis suggested usefulness of some analogues, mainly 11c, as antitumour drugs in limited range of tumours of certain tissue origin, such as WEHI 164.
Trzonkowski
P
P
Department of Histology and Immunology, Medical University of Gdańsk, ul. Debinki 1, 80-211 Gdańsk, Poland. ptrzon@amedec.amg.gda.pl
Dzierzbicka
K
K
Bociewicz
J
J
Szmit
E
E
Myśliwski
A
A
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000737:chemistry / Q000494:pharmacology*; D000328:Adult; D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D004354:Drug Screening Assays, Antitumor; D005434:Flow Cytometry; D006801:Humans; D020128:Inhibitory Concentration 50; D007962:Leukocytes / Q000187:drug effects; D008875:Middle Aged; D011799:Quinazolines / Q000737:chemistry / Q000494:pharmacology*; D013329:Structure-Activity Relationship
D000970:Antineoplastic Agents; D011799:Quinazolines; D000119:Acetylmuramyl-Alanyl-Isoglutamine; C057924:batracylin